TrialESMO open2026

EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma.

J E Rosenberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.